Company sets ambitious vision for €480 million in recurring revenues and a 40% EBITDA margin by 2030; outlines roadmap for accelerated AI-driven growth and innovation. Dublin, Ireland--(Newsfile Corp.
Continued triple digit growth from GI Genius®, double digit growth from Winlevi® and steady growth from Gastro and CDMO business. Increased R&D spending to advance Phase II programs for Bile Acid ...
Dublin, Ireland--(Newsfile Corp. - March 9, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today reports its audited financial results for the fiscal year ended December 31, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results